Literature DB >> 2831986

Mechanism of resistance of non-cycling mammalian cells to 4'-[9-acridinylamino]methanesulphon-m-anisidide: role of DNA topoisomerase II in log- and plateau-phase CHO cells.

E Schneider1, S J Darkin, M A Robbie, W R Wilson, R K Ralph.   

Abstract

CHO-AA8 cells were used as a model system to study the role of DNA topoisomerase II in the resistance of non-cycling cells to amsacrine. Plateau-phase AA8 cells have previously been shown to be resistant to amsacrine and to contain fewer DNA breaks than log-phase cells after drug treatment (Robbie, M.A., Baguley, B.C., Denny, W.A., Gavin, J.R. and Wilson, W.R. (1988) Cancer Res., in press). The phage P4-unknotting activity of nuclear extracts decreased 2-fold when AA8 cells entered into the non-cycling state, but there was no difference in sensitivity to amsacrine between log- and plateau-phase nuclear extracts. Drug stimulation of protein-DNA complex formation was similar in whole cells, isolated nuclei and nuclear extracts from either log- or plateau-phase cells. However, stimulation of complex formation in cells, nuclei or nuclear extracts was approx. 4-fold lower in plateau-phase than in log-phase. The data presented suggested that drug-enzyme interaction was altered in plateau-phase cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831986     DOI: 10.1016/0167-4781(88)90151-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation.

Authors:  E Schneider; H Yamazaki; B K Sinha; K H Cowan
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

Review 2.  TOP2B: The First Thirty Years.

Authors:  Caroline A Austin; Ka C Lee; Rebecca L Swan; Mushtaq M Khazeem; Catriona M Manville; Peter Cridland; Achim Treumann; Andrew Porter; Nick J Morris; Ian G Cowell
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.